On September 11, 2015 Array BioPharma Inc. (NASDAQ: ARRY) reported presentations on encorafenib and binimetinib at the 2015 European Cancer Congress (ECC), which will be held September 25 – 29, 2015 in Vienna, Austria (Press release, Array BioPharma, SEP 11, 2015, View Source;p=RssLanding&cat=news&id=2087227 [SID:1234507455]). These products are currently advancing in a total of three pivotal trials, with top-line results expected over the next year from the NEMO (binimetinib monotherapy in NRAS mutant melanoma) and COLUMBUS (binimetinib and encorafenib in BRAF mutant melanoma) Phase 3 trials.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Array BioPharma
Ron Squarer, Chief Executive Officer of Array, noted, "We are encouraged to see two ECC abstracts reporting clinical data from binimetinib and encorafenib. Importantly, the LOGIC2 presentation at ECC will provide a further opportunity to demonstrate the safety and clinical activity profile of this combination in a larger, independent data set."
The following is a summary of the presentations that will be given at ECC.
ORAL PRESENTATION
Title: A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma naive to BRAFi treatment (Abstract #3300)
Presenter: Carla van Herpen, MD
Date: Monday, September 28, 9 – 9:15 a.m. CEST (Oral Presentation)
Updated data will be provided at the conference, beyond what is included in the abstract.
POSTER PRESENTATION WITH SPOTLIGHT SESSION
Title: LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to overcome resistance in adult patients with locally-advanced or metastatic BRAF V600 melanoma (Abstract #3310)
Presenter: Reinhard Dummer, MD
Date: Sunday, September 27, 4:45 – 6:45 p.m. CEST
Abstract #3310 will also be included in the Poster Spotlight Session on Sunday, September 27, 5:15 – 6:15 p.m.
Updated data will be provided at the conference, beyond what is included in the abstract.
All abstracts can be accessed through the ECC website, View Source
– See more at: View Source;p=RssLanding&cat=news&id=2087227#sthash.FMOn4AWQ.dpuf